Summit Trail Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Summit Trail Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-400	Closed	-$34K	–	471
2018 Q2	$34K	Buy	+400	New	+$29.3K	0.01%	341
2018 Q1	–	Sell	-428	Closed	-$26K	–	1785
2017 Q4	$26K	Buy	+428	New	+$27K	﹤0.01%	977

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Summit Trail Advisors's ICPT Position: Q3 2018 in Review

Summit Trail Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2018, closing a stake of 400 shares — an estimated $34K sold.

Summit Trail Advisors first reported a position in ICPT in Q4 2017 and held it in 2 quarters. The position peaked at $34K in Q2 2018. 175 funds tracked by Wall St. Rank hold ICPT as of Q3 2018.

Summit Trail Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Summit Trail Advisors sold 400 Intercept Pharmaceuticals, Inc. shares in Q3 2018, an estimated $34K.
Summit Trail Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
Summit Trail Advisors's Intercept Pharmaceuticals, Inc. position peaked at $34K in Q2 2018.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.